Under CEO James Gorman, Morgan Stanley has emphasized its wealth management division, a far steadier business than its trading operations.Financeread more
Treasury Secretary Steven Mnuchin said a call between U.S. and China trade officials is scheduled for later on Thursday.Marketsread more
Netflix can sustain its lofty valuation only if global subscriber growth can support increasing content spending and debt.Technologyread more
China has other "weapons" in its trade battle with the United States — and selling off its U.S. Treasury holdings will not be one of them, said Richard McGregor, senior fellow...China Economyread more
Three candidates calling for a mixed approach also co-sponsored Sen. Bernie Sanders' 'Medicare for All' bill.2020 Electionsread more
Here are the biggest calls on Wall Street on ThursdayInvestingread more
Raymond James upgraded Apple and said its most recent checks show Apple is preparing to bring a 5G iPhone to a wider range of models than previously thought.Marketsread more
Barr and Ross had defied Democrats' subpoenas for information about the Trump administration's efforts to add a citizenship question to the 2020 census.Politicsread more
IBM's year-over-year revenue has now declined for four quarters in a row. Impact from Red Hat is not yet factored into the company's guidance.Technologyread more
Cheaper prescription drugs might seem like a good thing. But Wall Street analyst Michael Yee told CNBC that the trend of recent companies announcing they will lower or are considering lowering prices is not all it's cracked up to be.
"The important takeaway that investors should understand about the recent developments is that while there are either no price increases or in some cases, with Merck, price decreases, very interestingly, the drugs that they reduced prices on were either small drugs or very insignificant drugs, " Yee, an analyst at Jefferies, said Friday on "Power Lunch. "
In Merck's case, the U.S. pharmaceutical giant announced on Thursday that it would limit price hikes on select drugs or lower the price of some treatments, including a 60 percent price cut on hepatitis C treatment Zepatier.
But Yee pointed out that the medication had declining sales in its last earnings report, bringing in less than $300 million in sales, compared with $468 million in a previous report.
Merck declined to comment to CNBC on Yee's statements.
"Both the administration is trying to look good [and] drug companies are trying to look good," Yee said.
On July 9, Trump tweeted: "Pfizer & others should be ashamed that they have raised drug prices for no reason. They are merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere. We will respond!"
Pfizer responded to the tweet by saying that it would postpone price increases until after the CEO and the president spoke.
Other drug companies, Yee said, are now lowering prices because they "do not want to be publicly shamed on Twitter."
As a result, both Trump and drug companies are "appearing to look good, at least on the surface," Yee said.
The analyst is not optimistic that any major legislative changes will occur to how drugs are priced. Instead, he reasons, a compromise will be the likely outcome.
"People will feel better about [a compromise]," Yee said. "Midterm elections will pass, and we’ll go into 19 feeling a lot better about these things."